Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 in recurrent/metastatic squamous cell carcinoma of the head and neck after anti-EGFR therapy failure
2011-000902-24Phase 2Completed
- Sponsor
- Symphogen
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of futuximab + modotuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Symphogen. Primary endpoint: Progression-free survival rate at 24 weeks. Started Apr 2011; status: completed.
02
Drugs
futuximab + modotuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-000902-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000902-24.